Author： Ronel Natti
Publisher： Informa Healthcare
ISSN： 1606-6359
Source： Addiction Research and Theory, Vol.21, Iss.4, 2013-08, pp. : 295-305
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Self-monitoring for T2DM in Canada: what do the models say?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. :
Access to resources
Recommend
Cannabinoids in Multiple Sclerosis: Do They Have a Therapeutic Role?
By Killestein J. Uitdehaag B.M.J. Polman C.H.
Drugs, Vol. 64, Iss. 1, 2004-01 ,pp. :
What do Stakeholders Think about Pharmacovigilance?
Drug Safety, Vol. 33, Iss. 8, 2010-08 ,pp. :
Aldosterone Receptor Antagonists for Hypertension: What Do They Offer?
Drugs, Vol. 63, Iss. 19, 2003-01 ,pp. :
Prevention and Pharmacovigilance: What Should We Do, What Can We Do?
Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. :